Publications | PubMed=3583449; DOI=10.1002/ijc.2910390607 Wolf C.R., Hayward I.P., Lawrie S.S., Buckton K., McIntyre M.A., Adams D.J., Lewis A.D., Scott A.R.R., Smyth J.F. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer 39:695-702(1987) PubMed=3167863 Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 48:6166-6172(1988) PubMed=1348364; DOI=10.1073/pnas.89.7.3070 Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992) PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-# Mullen P., Ritchie A., Langdon S.P., Miller W.R. Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int. J. Cancer 67:816-820(1996) PubMed=9041185 Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57:850-856(1997) PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178 Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J., Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69:6381-6386(2009) PubMed=20581869; DOI=10.1038/onc.2010.245 Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29:4905-4913(2010) PubMed=22183581; DOI=10.1002/path.3980 Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J., Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J. Pathol. 226:703-712(2012) PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170 Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2:56-67(2012) PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017 Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol. Oncol. 127:241-248(2012) PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007 Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 7:567-579(2013) PubMed=25230021; DOI=10.1371/journal.pone.0103988 Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE 9:E103988-E103988(2014) PubMed=25960936; DOI=10.4161/21624011.2014.954893 Boegel S., Lower M., Bukur T., Sahin U., Castle J.C. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology 3:e954893.1-e954893.12(2014) PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028 Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol. Oncol. 142:332-340(2016) PubMed=27561551; DOI=10.1038/ncomms12645 Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7:12645.1-12645.14(2016) PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028 Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R. Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer. Cell Rep. 18:2343-2358(2017) CLPUB00667 Lisio M.-A. Evaluation of platinum-sensitivity in a cell line model of high grade serous ovarian cancer and the induction of resistance from a chemo- sensitive cell line through the repopulation of cells following short-term cisplatin treatment. Thesis PhD (2019), McGill University Montreal, Canada PubMed=30971826; DOI=10.1038/s41586-019-1103-9 Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568:511-516(2019) PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471 Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J., Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N., Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J., Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D., Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B., Wang P., Birrer M.J., Paulovich A.G. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep. Med. 2:100471.1-100471.32(2021) |